Načítá se...
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis is a rare, progressive and fatal lung disease which affects approximately 5 million persons worldwide. Although pirfenidone and/or nintedanib treatment improves patients’ wellbeing, the prognosis of IPF remains poor with 5-year mortality rates still ranging from 70 to 8...
Uloženo v:
| Vydáno v: | J Clin Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833050/ https://ncbi.nlm.nih.gov/pubmed/31561518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101547 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|